137 related articles for article (PubMed ID: 38423598)
1. Thioredoxin Reductase Inhibitor Suppresses the Local Progression of Rhabdomyosarcoma With PDX Models.
Kinoshita H; Kinoshita S; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
Cancer Genomics Proteomics; 2024; 21(2):178-185. PubMed ID: 38423598
[TBL] [Abstract][Full Text] [Related]
2. The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression.
Kinoshita H; Shimozato O; Ishii T; Kamoda H; Hagiwara Y; Tsukanishi T; Ohtori S; Yonemoto T
Anticancer Res; 2021 Oct; 41(10):4947-4955. PubMed ID: 34593442
[TBL] [Abstract][Full Text] [Related]
3. The Combination of Auranofin and Celecoxib Suppresses Local Synovial Sarcoma Progression
Kinoshita H; Kinoshita S; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
Anticancer Res; 2024 Jun; 44(6):2453-2458. PubMed ID: 38821602
[TBL] [Abstract][Full Text] [Related]
4. Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death.
Habermann KJ; Grünewald L; van Wijk S; Fulda S
Cell Death Dis; 2017 Oct; 8(10):e3067. PubMed ID: 28981107
[TBL] [Abstract][Full Text] [Related]
5. Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase.
Malin D; Lee Y; Chepikova O; Strekalova E; Carlson A; Cryns VL
Breast Cancer Res Treat; 2021 Dec; 190(3):373-387. PubMed ID: 34553295
[TBL] [Abstract][Full Text] [Related]
6. Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary Metastases of Osteosarcoma
Kinoshita H; Kinoshita S; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
Anticancer Res; 2024 Mar; 44(3):1045-1049. PubMed ID: 38423669
[TBL] [Abstract][Full Text] [Related]
7. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism.
Sobhakumari A; Love-Homan L; Fletcher EV; Martin SM; Parsons AD; Spitz DR; Knudson CM; Simons AL
PLoS One; 2012; 7(10):e48175. PubMed ID: 23118946
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
Yan X; Zhang X; Wang L; Zhang R; Pu X; Wu S; Li L; Tong P; Wang J; Meng QH; Jensen VB; Girard L; Minna JD; Roth JA; Swisher SG; Heymach JV; Fang B
Cancer Res; 2019 Jan; 79(1):125-132. PubMed ID: 30401714
[TBL] [Abstract][Full Text] [Related]
10. Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms.
Yang L; Wang H; Yang X; Wu Q; An P; Jin X; Liu W; Huang X; Li Y; Yan S; Shen S; Liang T; Min J; Wang F
Signal Transduct Target Ther; 2020 Jul; 5(1):138. PubMed ID: 32732975
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
12. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Castillo-Ecija H; Pascual-Pasto G; Perez-Jaume S; Resa-Pares C; Vila-Ubach M; Monterrubio C; Jimenez-Cabaco A; Baulenas-Farres M; Muñoz-Aznar O; Salvador N; Cuadrado-Vilanova M; Olaciregui NG; Balaguer-Lluna L; Burgueño V; Vicario FJ; Manzanares A; Castañeda A; Santa-Maria V; Cruz O; Celis V; Morales La Madrid A; Garraus M; Gorostegui M; Vancells M; Carrasco R; Krauel L; Torner F; Suñol M; Lavarino C; Mora J; Carcaboso AM
J Pathol Clin Res; 2021 Jul; 7(4):338-349. PubMed ID: 33837665
[TBL] [Abstract][Full Text] [Related]
14. Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS).
Lacey A; Hedrick E; Li X; Patel K; Doddapaneni R; Singh M; Safe S
Oncotarget; 2016 May; 7(21):31257-69. PubMed ID: 27144436
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.
Xu N; Hua Z; Ba G; Zhang S; Liu Z; Thiele CJ; Li Z
J Exp Clin Cancer Res; 2019 Mar; 38(1):118. PubMed ID: 30850026
[TBL] [Abstract][Full Text] [Related]
16. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
[TBL] [Abstract][Full Text] [Related]
17. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.
Kiebala M; Skalska J; Casulo C; Brookes PS; Peterson DR; Hilchey SP; Dai Y; Grant S; Maggirwar SB; Bernstein SH
Exp Hematol; 2015 Feb; 43(2):89-99. PubMed ID: 25448488
[TBL] [Abstract][Full Text] [Related]
18. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
Seitz G; Warmann SW; Vokuhl CO; Heitmann H; Treuner C; Leuschner I; Fuchs J
Pediatr Surg Int; 2007 May; 23(5):431-9. PubMed ID: 17211591
[TBL] [Abstract][Full Text] [Related]
19. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.
Shen J; Hong Y; Zhao Q; Zhang JL
Tumour Biol; 2016 Jan; 37(1):1025-33. PubMed ID: 26269112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
